<DOC>
	<DOC>NCT02736539</DOC>
	<brief_summary>This study is designed as a randomized double-blinded treatment trial among travelers' to geographical areas with moderate-severe rates of traveler's diarrhea. Travelers will be randomized to receive Bimuno® or masked placebo to be taken daily while traveling. The test article or placebo will be taken starting 7 days prior to travel.</brief_summary>
	<brief_title>Clinical Trial of CBS-2004 (Bimuno)® in Prevention of Travelers' Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Dysentery</mesh_term>
	<criteria>1. Healthy subjects, 18 years old or older 2. Travel on moderatehigh risk itinerary for traveler's diarrhea for minimum of 14 days and maximum of 6 weeks travel 3. Able to comply with study and followup procedures 4. Subjects willing and able to enter data in the diary card 5. An IRB approved informed consent form is signed and dated 6. Subjects must have adequate general health (as determined by investigators) 7. Women: Nonnursing and negative urine/serum pregnancy test with understanding through informed consent process to avoid pregnancy during the study while on the study drug. Should an individual have a documented surgical sterilization in her medical record, a pregnancy test will not be required. If a volunteer becomes pregnant during the study, the Principal Investigator (PI) will notify the study research monitor and the Institutional Review Boards (IRBs). The pregnancy outcome will be followed per IRB and other regulatory requirements. 1. Allergy to investigational product 2. History of functional bowel disorder (including IBS) 3. Chronic intestinal disease (ulcerative colitis, crohn's disease), post vagotomy diabetic autonomic neuropathy, malabsorption, short bowel syndrome, celiac disease, bacterial overgrowth due to blind loops, pancreatitis 4. Antibiotic use within 7 days prior to enrollment (except for malaria prophylaxis excluding doxycycline) 5. Use of other probiotics or prebiotics (outside of the study product) in the prior 3weeks or intent to use during the study period. This includes the overthecounter preparations of probiotics, prebiotics (including inulin, lactulose) or consumption of a bioyogurt product. 6. Lactose intolerant (allergies to dairy products). 7. Medications usage as deemed by the PI to interfere with GI function 8. Diarrheal illness within 7 days prior to enrollment 9. Subject has a concomitant disease or condition that could interfere with or for which treatment could interfere with the conduct of the study, or could in the opinion of the investigator increase the risk of adverse events (AEs) during the subject's participation in the study. 10. Use of any investigational or nonregistered drug other than the study drug within 30 days preceding the study enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>